The trial showed that patients with an IDH1(R132H)-specific immune response had an excellent two-year progression-free rate of 0.82, and this vaccine-induced response was associated with the presence of T-helper cells at the tumor site, thereby altering the tumor microenvironment. This evidence concerns the gene IDH1 and neoplasm.